LIVER15 2015 - New Treatments in Chronic Liver Disease

Website http://www.scripps.org/events/new-treatments-in-chronic-liver-disease-march-20-2015 | Edit Freely

Category Liver Disease

Deadline: March 21, 2015 | Date: March 22, 2015-March 23, 2015

Venue/Country: La Jolla, U.S.A

Updated: 2014-09-24 04:39:11 (GMT+9)

Call For Papers - CFP

There was a fundamental change in the treatment of chronic hepatitis C in 2014 with the addition of 2 new direct-acting antiviral (DAAs) drugs to current standard of care for all genotypes. There will be two separate lectures devoted to this topic this year. The first will be on triple therapies that were approved in late 2013. The second will be on future therapies using two or more DAA’s without interferons.

We anticipate that there will be a number of new demands placed on treatment providers, including screening, access to treatment, costs of therapy and the continuation of complex algorithms for interferon-based regimens. Looking beyond 2014, we see numerous combinations of DAA’s in development including protease inhibitors, nucleoside polymerase inhibitors, non-nucleoside polymerase inhibitors and N55A inhibitors. All of these agents are in phase 3 development and a number have completed studies and are awaiting FDA review. In hepatitis B, the treatments have not changed but there is more mature data available on renal resistance, long-term HBsAg loss and clinical outcomes. The addition of hepatitis E as an important disease and a treatable form of viral hepatitis has been included in this year’s program. New therapies for NAFLD and NASH are in development and will be explored. The explosive growth of NASH in the US has created a significant need for effective drug therapy. The diagnosis and treatment of hepatocellular carcinoma will be updated as this disease is one of the few cancers with a growing incidence in the US. New oral therapy is moving this field forward. There will be an update on management of hepatic encephalopathy, hyponatremia and the management of pulmonary complications in the transplant candidate."